The overall goal of the Pharmacology and Analytical Center Facility is to provide the broad base of sophistical analytical equipment and expertise in pharmacology and medicinal chemistry required for preclinical and clinical investigations of anti-cancer drugs and related therapies. This goal will be accomplished by focusing on three aims. First, the Pharmacology and Analytical Center Facility will enable expanded analytical support for basic and clinical scientists at The University of Texas M.D. Anderson Cancer Center. This support will include access to instruments for nuclear magnetic resonance (NMR), liquid chromatography (LC)/mass spectrometry (MS), gas chromatography (GC), GC/MS, and high- performance liquid chromatography (HPLC). Support will also include assistance with the verification of structural identify, purification, and determination of stability of drugs and drug metabolites, as well as assistance with developing assays, solving proof-of-identity problems, and developing validation procedures. Second, scientists running the Pharmacology and Analytical Center Facility will provide a resource for investigators seeking pharmacokinetic and pharmacodynamic information on specific compounds and knowledge off how to best use such information for optimal protocol design, dose adjustments to increase efficacy or decrease toxicity, and similar clinical problems. Finally, the Pharmacology and Analytical Center Facility will provide a pharmacology resource for information about and techniques for studying nucleic acid components, such as bases, nucleosides, nucleotides, and oligonucleotides. This services will also include quantitation of the radioactivity associated with proteins, and Betascope and radiometric flow analytical instrumentation will be available. The analytical instruments of the Pharmacology and Analytical Center Facility are conveniently housed on the same (seventh) floor of M.D. Anderson Cancer Center in laboratories run by Director Robert Newman and co-directors William Plunkett, Timothy Madden, and David Farquhar. The equipment and analytical support to be provided by the facility are deemed critical for the success of many of the disease site- and them-specific programs proposed in this application. Formation of the Pharmacology and Analytical Center Facility will augment the ability of M.D. Anderson investigators to collaborate on studies involving pharmacologic analyses.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016672-26S2
Application #
6506690
Study Section
Project Start
2001-09-28
Project End
2002-06-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Garg, Rachana; Blando, Jorge M; Perez, Carlos J et al. (2018) COX-2 mediates pro-tumorigenic effects of PKC? in prostate cancer. Oncogene 37:4735-4749
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Subbiah, Ishwaria M; Tang, Chad; Rao, Arvind et al. (2018) Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. Oncotarget 9:28842-28848
Daver, Naval; Boddu, Prajwal; Garcia-Manero, Guillermo et al. (2018) Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia 32:1094-1105
Bailey, Matthew H; Tokheim, Collin; Porta-Pardo, Eduard et al. (2018) Comprehensive Characterization of Cancer Driver Genes and Mutations. Cell 173:371-385.e18
Ohri, Nisha; Sittig, Mark P; Tsai, Chiaojung Jillian et al. (2018) Trends and variations in postmastectomy radiation therapy for breast cancer in patients with 1 to 3 positive lymph nodes: A National Cancer Data Base analysis. Cancer 124:482-490
Cao, Qizhen; Yan, Xinrui; Chen, Kai et al. (2018) Macrophages as a potential tumor-microenvironment target for noninvasive imaging of early response to anticancer therapy. Biomaterials 152:63-76
Vichaya, Elisabeth G; Dantzer, Robert (2018) Inflammation-induced motivational changes: Perspective gained by evaluating positive and negative valence systems. Curr Opin Behav Sci 22:90-95
Nguyen, Jennifer; Jiao, Jingjing; Smoot, Kristin et al. (2018) Toll-like receptor 4: a target for chemoprevention of hepatocellular carcinoma in obesity and steatohepatitis. Oncotarget 9:29495-29507
Reddy, S M; Barcenas, C H; Sinha, A K et al. (2018) Long-term survival outcomes of triple-receptor negative breast cancer survivors who are disease free at 5 years and relationship with low hormone receptor positivity. Br J Cancer 118:17-23

Showing the most recent 10 out of 12418 publications